Ventilator Associated Pneumonia (Sub-Category)

Ventilator-Associated Pneumonia Education Module

Dr. Kevin Duplisea, BScPhm ACPR PharmD

Developed by:  Kevin Duplisea, BScPhm ACPR PharmD with contributions from the CAHO ASP Project Team

KEY MESSAGES

  • Immediate sampling of airway secretions prior to initiation of antimicrobials is important to be able to narrow antimicrobial therapy based on culture and sensitivity results.
  • Getting the right drug up front probably matters.  Appropriate and timely initiation of empiric therapy for VAP is associated with better patient outcomes.
  • CPIS can help risk-stratify patients and reduce unnecessary use of antimicrobials.
  • Monotherapy has similar efficacy to combination therapy.  The exception to this recommendation is empiric therapy for patients who are at high risk for infections with Ps. aeruginosa or multi-drug resistant (MDR) pathogens or in ICUs where Ps. aeruginosa or MDR pathogens are endemic.
  • Shorten durations of therapy.  In patients with proven VAP, including those caused by Ps. aeruginosa or S. aureus, an overall duration of antibiotic treatment of seven full days is generally sufficient.

Full PDF Article:

Council of Academic Hospitals of Ontario (CAHO) Antimicrobial Stewardship in the Intensive Care Unit ARTIC Project: Ventilator Associated Pneumonia Education Module